

Hyperglycemia and adverse Pregnancy Outcome follow-up study (HAPO FUS)

DOI:

[10.2337/dc18-2021](https://doi.org/10.2337/dc18-2021)

Document Version

Accepted author manuscript

[Link to publication record in Manchester Research Explorer](#)

Citation for published version (APA):

HAPO Follow-Up Study Cooperative Research Group, & Clayton, P. (2019). Hyperglycemia and adverse Pregnancy Outcome follow-up study (HAPO FUS): Maternal glycemia and childhood glucose metabolism. *Diabetes Care*, 42(3), 381-392. <https://doi.org/10.2337/dc18-2021>

Published in:

Diabetes Care

Citing this paper

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy

If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [<http://man.ac.uk/04Y6Bo>] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.



Hyperglycemia & Adverse Pregnancy Outcome Follow-Up Study (HAPO FUS):

Maternal Gestational Diabetes and Childhood Glucose Metabolism

Running Title: HAPO FUS child glucose metabolism

Writing group on behalf of the HAPO Follow-Up Study Cooperative Research

Group

Word count (text): 3995

Tables/figures: 4

Writing Group:

William L Lowe, Jr, MD¹

Denise M Scholtens, PhD¹

Alan Kuang, MS¹

Barbara Linder, MD, PhD²

Jean M Lawrence, ScD³

Yael Lebenthal, MD⁴

David McCance, MD⁵

Jill Hamilton, MD⁶

Michael Nodzenski, MS¹

Octavious Talbot, MS¹

Wendy J Brickman, MD^{1,7}

Peter Clayton, MD⁸

Ronald C Ma, MB⁹

WH Tam, MD⁹

Alan R Dyer, PhD¹

Patrick M Catalano, MD¹⁰

Lynn P Lowe, PhD¹

Boyd E Metzger, MD¹, Corresponding Author
Northwestern University Feinberg School of Medicine, Chicago, IL, USA 60611
Phone: 1-312-503-7979, office; 1-847-989-5488, cell
Email: bem@northwestern.edu

The Writing Group takes responsibility for the content of this article.

¹Northwestern University Feinberg School of Medicine, Chicago, IL, USA

²NIDDK, National Institutes of Health, Bethesda, MD, USA

³Kaiser Permanente Southern California, Pasadena, CA, USA

⁴Schneider Children's Medical Center of Israel, Petah Tiqva, Israel and Sackler Faculty of Medicine, Tel Aviv University, Israel

⁵Royal Victoria Hospital, Belfast, United Kingdom

⁶The Hospital for Sick Children, University of Toronto, Ontario, Canada

⁷Ann and Robert H Lurie Children's Hospital, Chicago, IL, USA

⁸Royal Manchester Children's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre/School of Medical Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom

⁹The Chinese University of Hong Kong/Prince of Wales Hospital, Hong Kong, China

¹⁰MetroHealth Medical Center/Case Western Reserve University, Cleveland, OH, USA

Abstract

Objective

Whether hyperglycemia *in utero* less than overt diabetes is associated with altered childhood glucose metabolism is unknown. We examined associations of gestational diabetes (GDM) not confounded by treatment with childhood glycemia in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) cohort.

Research Design and Methods

HAPO Follow-Up Study (FUS) included 4160 children ages 10-14 years who completed all or part of an oral glucose tolerance test (OGTT) and whose mothers had a 75-g OGTT at ~28 weeks gestation with blinded glucose values. Primary predictor was GDM by World Health Organization criteria. Child outcomes were impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and type 2 diabetes. Additional measures included insulin sensitivity and secretion and oral disposition index.

Results

For GDM mothers, 10.6% of children had IGT compared with 5.0% of children of mothers without GDM; IFG frequencies were 9.2% and 7.4%, respectively. Type 2 diabetes cases (10) were too few for analysis. Odds ratios (95% CI) adjusted for family history of diabetes, maternal BMI and child BMI z-score were 1.09 (0.78-1.52) for IFG and 1.96 (1.41-2.73) for IGT. GDM was positively associated with child's 30-min, 1-h, and 2-h but not fasting glucose and inversely associated with insulin sensitivity and oral

disposition index [adjusted mean differences (95% CI) -76.3 (-130.3- -22.4) and -0.12 (-0.17- -0.064)], respectively, but not insulinogenic index.

Conclusions

Offspring exposed to untreated GDM *in utero* are insulin resistant with limited beta cell compensation compared with offspring of non-GDM mothers. GDM is significantly and independently associated with childhood IGT.

The incidence of type 2 diabetes among youth is rising, due, in part, to increasing prevalence of childhood obesity (1-3). Worldwide, it is estimated that type 2 diabetes in children will continue to increase, posing a significant public health and financial burden (4). In addition to childhood obesity, intrauterine exposure to maternal pre-existing diabetes or gestational diabetes mellitus (GDM) is associated with higher risk for offspring abnormal glucose metabolism (5). Early evidence for these associations came from two long-term studies: a longitudinal study of Pima Indians (6) and cohort study of a mixed ethnic population in Chicago (7). However, these studies focused on women with a high prevalence of diabetes, making it unclear whether these results could be extrapolated to other populations. More recently, maternal treatment during pregnancy has confounded studies examining the impact of the intrauterine milieu on offspring risk of hyperglycemia (8). Studies have also not adequately addressed whether hyperglycemia *in utero* less than overt diabetes is associated with altered glucose metabolism in childhood.

The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Follow-Up Study (FUS) offered a unique opportunity to examine associations of maternal glycemia during pregnancy, less than overt diabetes and not confounded by maternal treatment, with childhood glucose metabolism. The HAPO Study, an observational epidemiological study that recruited a large, multinational, racially and ethnically diverse cohort, demonstrated that glucose levels below those diagnostic of diabetes were associated with adverse pregnancy outcomes (9). Based on these results and others, new diagnostic criteria for GDM were proposed by the International Association of Diabetes

in Pregnancy Study Groups (IADPSG) (10) and adopted by the World Health Organization (WHO) and others (11). These IADPSG/WHO criteria, based on newborn outcomes, reduced both the glucose levels and required number of abnormal values (from two to one) to diagnose GDM compared to Carpenter-Coustan criteria (12). This report from the HAPO FUS examines whether *in utero* exposure to untreated GDM, defined post-hoc by IADPSG/WHO criteria, is associated with pre-specified glucose outcomes (impaired fasting glucose [IFG], impaired glucose tolerance [IGT] or type 2 diabetes) in children ages 10-14 years.

METHODS

HAPO was a population-based study in which women underwent a 75-g oral glucose tolerance test (OGTT) at ~28 weeks gestation (9). Fasting plasma glucose (FPG), 1-h, and 2-h plasma glucose (PG) were measured at a central laboratory (9). OGTT results remained blinded to caregivers and participants unless FPG >5.8 mmol/l and/or 2-h PG >11.1 mmol/l, either measure was <2.5 mmol/l, or random PG at 34-37 weeks gestation was >8.9 mmol/l (9). Using these criteria, 427 (1.8%) participants were unblinded based on FPG and/or 2-h PG. Blinded participants were untreated. Height, weight, and blood pressure were measured using standardized procedures. Demographic and lifestyle characteristics, including age, self-reported race/ethnicity, and any smoking or alcohol use during pregnancy, were collected via questionnaire and parity by medical record abstraction.

Participants

HAPO FUS participants were recruited during 2013-2016 from 10 of 15 HAPO field centers based on feasibility to recruit participants. Eligibility criteria for HAPO FUS included caregivers and participants being blinded to HAPO OGTT results, gestational age at delivery ≥ 37 weeks and no major neonatal malformations or fetal/neonatal death. This yielded 15,812 eligible mother-child pairs. The recruitment target was 7,000 pairs, based on the primary childhood outcome of overweight/obesity (13). Multiple attempts were made to contact all eligible participants through IRB-approved means. Of the 15,812 eligible mother-child pairs, 6490 could not be contacted and 4488 declined participation (Supplementary Fig. 1). A total of 4834 children completed all or part of the HAPO FUS visit. OGTT completion was not required for participation. One child was excluded due to inadequate fasting and a second for lack of cooperation. Of the remaining 4832 children, data were analyzed from 4160 who had a FPG and at least one other timed OGTT measurement or who reported diabetes on treatment and were not excluded as having type 1 diabetes by antibody testing (see below).

The protocol was approved by each center's IRB. All mothers gave written informed consent for their child, and children assented where required by the local IRB. There was an external Observational Study Monitoring Board.

Study Visit

Height was measured twice without shoes to the nearest 0.5 cm with a stadiometer and again if results differed by >1.0 cm. Weight was measured twice to the nearest 0.1 kg and again if results differed by >0.5 kg. Participants underwent a 2-h OGTT with a

glucose load of 1.75 g/kg body weight (maximum 75g) following an 8-h overnight fast with samples drawn for glucose and C-peptide at fasting, and 30-min, 1-h, and 2-h. If the child had self-reported diabetes on drug treatment, only a non-fasting blood sample was collected. All samples were processed at the field center laboratory and stored at -80°C until shipment to the Central Laboratory.

Skinfolds (triceps, subscapular, suprailiac) were measured twice with calibrated calipers (Harpenden, London, UK) to the nearest 0.1 mm and again if results differed by >1.0 mm. Percent fat was measured by air displacement plethysmography (BOD POD, Cosmed, Italy). Tanner staging was performed by trained individuals using breast/areolar development for girls and testicular volume (Prader orchidometer) for boys. Child's age, first degree family history of diabetes, and menstrual history for girls were collected from the mother via questionnaire.

Laboratory Measurements

Glucose was measured by hexokinase in the Clinical Chemistry Laboratory of Northwestern Memorial Hospital on a Beckman-Coulter SYNCHRON LX analyzer. Blinded duplicate samples were assayed several weeks apart and coefficients of variation (CVs) calculated within pairs for a random 10% subset; mean CV was 1.5% for FPG, 1-h and 2-h PG and 1.3% for 30-min PG. C-peptide was measured in the Comprehensive Metabolic Core at Northwestern using the electrochemiluminescence immunoassay method on a Roche cobas e411 immunoassay analyzer (14). Mean CVs were 2.8% for fasting, 2.9% for 30-min, 3.0% for 1-h and 3.2% for 2-h C-peptide. To

diagnose type 1 diabetes, serum anti-GAD65, -insulin, -ZnT8 and -IA-2 antibodies were measured at the Barbara Davis Center for Diabetes (Aurora, CO) for children reported to have diabetes on treatment (n=9) and for children with OGTT values indicative of incident diabetes (n=5). Of these 14 children, four had positive antibody results and were excluded from analyses.

Outcomes and Predictors

Dichotomous childhood outcomes were: IGT (2-h glucose 7.8-11.0 mmol/l); IFG by American Diabetes Association (ADA) and International Society for Pediatric and Adolescent Diabetes criteria (IFG-ADA, FPG 5.6-6.9 mmol/l); IFG by WHO criteria (IFG-WHO, FPG 6.1-6.9 mmol/l); type 2 diabetes (FPG \geq 7.0 mmol/l and/or 2-h PG \geq 11.1 mmol/l). Continuous outcomes included FPG, 30-minute, 1-h, and 2-h PG from the OGTT at individual time points. The sum of individual glucose z-scores, an integrated measure that gives equal weight to each of the four glucose values during the OGTT, was also examined. This involved calculating 'z-scores' at each OGTT time point by subtracting the mean glucose level from all observed values at that time point, dividing by the standard deviation of the glucose values at that time point, and summing the four individual 'z-scores'.

Matsuda, insulinogenic and disposition indices were examined as continuous outcomes. The Matsuda index estimates insulin sensitivity using glucose and insulin levels from an OGTT (15). A modified Matsuda index was calculated using OGTT glucose and C-peptide levels (15). The insulinogenic index was calculated using C-

peptide levels and defined as the Δ C-peptide (0 – 30 min, nmol/l)/ Δ glucose (0-30 min, mmol/l) (16). The disposition index was calculated as the product of the Matsuda index and insulinogenic index and then log transformed (17).

The primary predictor for child glucose outcomes was mother's GDM status during the HAPO pregnancy using IADPSG/WHO criteria where one or more glucose values from a 75g OGTT equaled or exceeded the following thresholds: FPG 5.1 mmol/l, 1-h PG 10.0 mmol/l, 2-h PG 8.5 mmol/l.

Exploratory analyses were conducted by removing women from the data set who met Carpenter-Coustan GDM criteria, defined in this study as two abnormal glucose values from a 2-hr 75g OGTT that equaled or exceeded the following thresholds: FPG 5.3 mmol/l, 1-h PG 10.0 mmol/l and 2-h PG 8.6 mmol/l. A predictor for mothers who only met IADPSG/WHO GDM criteria and not Carpenter-Coustan criteria, versus mothers without GDM, was then evaluated.

Statistical Analyses

Data were summarized using frequencies and counts for categorical variables and means and standard deviations (SDs) for continuous variables. Histograms and boxplots were examined to assess distributions and identify potential outliers. Multiple logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for dichotomous outcomes and modified least-squares regression with Huber-White robust standard errors was used to estimate risk differences with 95% CIs

(18). Multiple linear regression was used for continuous outcomes to estimate adjusted mean differences with 95% CIs. Two-sided $p < 0.05$ was used for evaluating statistical significance. All statistical analyses were conducted in R(3.4.1) (19).

Multiple models were considered for all outcomes, with variables identified according to study design, known potential confounders and adjustments used in HAPO analyses (9). Covariate adjustments were: Model 1: field center (proxy for race/ancestry since most centers were predominantly one race/ancestry group), child age, sex, and pubertal status (Tanner stage 1, 2/3, 4/5) with sex by Tanner stage interaction term, and maternal variables at pregnancy OGTT (age, height, mean arterial pressure, parity (0, 1+), smoking (yes/no), drinking alcohol (yes/no), gestational age), child's family history of diabetes in first degree relatives; Model 2: Model 1 + maternal BMI at pregnancy OGTT; Model 3: Model 1 + child's BMI z-score; Model 4: Model 1 + maternal BMI at pregnancy OGTT + child's BMI z-score. Child BMI z-scores were calculated according to LMS curves used by the International Obesity Task Force (20). Adjustments for other child adiposity variables were also explored, substituting child's percent body fat in Models 5-6 and child's sum of skinfolds in Models 7-8 for child's BMI z-score. While the study was not powered to evaluate Tanner stage-specific associations, an interaction term between GDM status and Tanner stage was evaluated to explore potential effect modification by Tanner stage. Exploratory analyses were also performed within Tanner Stage 1, 2/3 and 4/5 groups, using model covariates just listed but removing main effects for Tanner stage and sex x Tanner stage interactions. Multiple imputation was used to account for missing Tanner stage data, using a 'missing at random' assumption

after confirming findings varied little under 'missing not at random' (13). Logistic regression model fit was measured using C-statistics and confirmed by Hosmer-Lemeshow goodness-of-fit tests (21). Co-linearity of model predictors was evaluated using pairwise correlations.

RESULTS

Participants

Characteristics of participating children (mean age 11.4 years) and their mothers during the HAPO Study, overall and by GDM status, are shown in Table 1. At the HAPO OGTT, mothers with GDM were on average older with higher weight, BMI, and mean arterial pressure. Among mothers of children who did and did not participate, mean age and frequency of GDM were 30.0 years and 14.9% and 29.1 years and 16.9%, respectively (weighted summaries, Table S1). Mean maternal BMI, FPG, 1-h, and 2-h PG during the HAPO OGTT and race/ethnicity were similar.

Offspring of mothers with and without GDM had similar age and height. Offspring of mothers with GDM were heavier, had higher sum of skinfolds, more frequent family history of diabetes in first degree relatives, as well as lower insulin sensitivity (Matsuda index), insulin secretion (insulinogenic index), and beta cell compensation for insulin resistance (disposition index), compared with offspring of mothers without GDM.

IFG-ADA was present in 54 (9.2%) of offspring of mothers with GDM compared with 262 (7.4%) offspring of mothers without GDM, while 61 (10.6%) offspring of GDM mothers had IGT compared with 177 (5.0%) offspring of mothers without GDM (Table 1). IFG-WHO was present in 3 (0.5%) offspring of mothers with GDM and 20 (0.6%) offspring of mothers without GDM. Type 2 diabetes was present in 2 (0.3%) offspring of mothers with GDM and 8 (0.2%) offspring of mothers without GDM.

Model Diagnostics

Hosmer-Lemeshow p-values for logistic regression models ranged 0.59-0.97 for all outcomes, indicating reasonable model fit. C-statistics for logistic regression models ranged 0.70-0.78 and changed very little for each outcome for Models 1-4. R^2 values ranged 0.071-0.23 for continuous outcomes and changed very little across Models 1-4. Co-linearity was not a concern with pairwise correlations ranging from 0-0.20 for model covariates. Visual inspection of residual plots confirmed linear modeling assumptions and DFBeta statistics indicated no observations of undue influence.

Association of Maternal GDM Status with Childhood Glucose Levels

Offspring of mothers with GDM had higher 30-min, 1-h, and 2-h PG during their OGTT and sum of glucose z-scores compared with offspring of mothers without GDM. GDM was positively associated with child 30-min, 1-h, and 2-h PG and sum of glucose z-scores but not child FPG (Table 2). For the above associations, adjusting for maternal BMI at the time of the pregnancy OGTT (Model 2), child's BMI z-score (Model 3) or both maternal BMI and child's BMI z-score (Model 4) had little effect. Results were similar

after adjusting for either child percent body fat or sum of skinfolds at follow-up instead of child's BMI z-score (Table S2), demonstrating independence of the associations from maternal and child BMI and adiposity.

Association of Maternal GDM Status with Childhood Dichotomous Glucose Outcomes

GDM was associated with offspring IGT. After Model 1 adjustments, the OR [CI] and risk difference [CI] for IGT in offspring were 1.91 [1.38-2.64] and 0.046 [0.020-0.071], respectively. Adjusting for maternal BMI and/or child's BMI z-score (Models 2-4) did not attenuate associations (Fig. 1, ORs 1.87-1.96 and risk differences 0.044-0.047). In contrast, GDM was not associated with a higher risk for IFG-ADA (ORs 1.09-1.11, risk differences 0.0057-0.0066). The ORs and risk differences for IGT and IFG-ADA were similar after adjusting for child percent body fat or sum of skinfolds instead of child BMI z-score (Models 5-8, Table S3). Due to small sample sizes for IFG-WHO and type 2 diabetes, associations of GDM with these outcomes were not analyzed.

Association of Maternal GDM Status with Childhood Insulin Sensitivity and Secretion

GDM was inversely associated with child insulin sensitivity after adjusting for covariates in Model 1. This association was attenuated by adjusting for maternal BMI (Model 2) and/or child BMI z-score (Models 3 and 4) but remained significant, demonstrating independence from these two measures. Adjusting for either child percent body fat or sum of skinfolds at follow-up also attenuated the associations, but they remained significant (Table S2). GDM was not associated with the insulinogenic index except for a borderline significant inverse association after adjusting for both maternal BMI and

child BMI z-score ($p=0.06$). Results were comparable after adjusting for child percent body fat or sum of skinfolds (Table S2). GDM was significantly inversely associated with the disposition index in all models, including after adjusting for child percent body fat and sum of skinfolds (Tables 2 and S2).

Puberty affects insulin sensitivity and glucose metabolism (22). Thus, additional exploratory analyses were conducted separately for Tanner stages 1, 2/3 and 4/5. These analyses suggested that some of the associations described above may be strongest after onset of puberty (Model 4 results in Table S4). However, for all childhood outcomes, statistical interaction terms between GDM and Tanner stage were not significant.

Association of Maternal GDM Status according to IADPSG/WHO but not Carpenter-Coustan Criteria with Childhood Glucose Outcomes

The diagnosis of GDM using Carpenter-Coustan criteria requires 2 abnormal glucose values: FPG >5.3 mmol/l, 1-h PG >10.0 mmol/l, 2-h PG >8.6 mmol/l or 3-h PG >7.8 mmol/l. The present study was not powered to assess differences in childhood glucose outcomes for women with Carpenter-Coustan GDM, GDM by IADPSG/WHO criteria only, and no GDM. However, exploratory analyses were conducted by examining childhood dichotomous outcome frequencies and childhood continuous outcome means across the three groups. In addition, fully adjusted Model 4 logistic and linear regression results were examined after removing women meeting Carpenter-Coustan GDM criteria to evaluate associations with childhood outcomes for mothers with GDM

by IADPSG/WHO criteria only compared with those without GDM. In general, childhood dichotomous outcome frequencies and continuous outcome means for IADPSG/WHO only GDM were between those for mothers with Carpenter-Coustan GDM and mothers without GDM, except for FPG and insulinogenic index (Table S5). As observed for analyses including Carpenter-Coustan GDM mothers, GDM according to IADPSG/WHO criteria only was not associated with IFG or FPG in the fully adjusted Model 4. However, GDM according to IADPSG criteria only was associated with IGT, 30-min, 1-hr and 2-hr PG, glucose sum of z-scores and disposition index. ORs and adjusted mean differences were attenuated compared with analyses including mothers with Carpenter-Coustan GDM, but results still indicate statistically significant higher risks of adverse metabolic outcomes for children of mothers with GDM according to IADPSG criteria alone.

CONCLUSIONS

This study demonstrated that offspring of mothers with untreated GDM by IADPSG/WHO criteria are at high risk for IGT 10-14 years postpartum. In the United States over a timeframe similar to HAPO, GDM prevalence using Carpenter-Coustan criteria was 7.4% (23). In contrast, IADPSG/WHO criteria, which require only one abnormal glucose value during a 2-h OGTT, identify a larger group of mothers, e.g., 17.8% of women in the HAPO cohort (24). Thus, offspring of women meeting IADPSG/WHO criteria for GDM represent a sizable group at risk for IGT during childhood, which is important from a public health perspective, given the risk for progression to type 2 diabetes in children with IGT (25). The frequency of offspring type

2 diabetes in the present study was low, which precluded analyses of association of offspring type 2 diabetes with GDM.

Previous studies have examined the association between GDM or pre-existing diabetes *in utero* and later risk of altered offspring glucose metabolism (5; 26-28). Associations of pre-existing maternal type 2 diabetes or GDM with offspring glyceemic outcomes have been inconsistent, relating, in part, to the size of the studies and failure to adjust for maternal BMI (29). A recent meta-analysis of studies performed prior to development of IADPSG/WHO criteria examined associations of GDM with glucose outcomes in children from pre-puberty through young adulthood (30). Among 5850 children, GDM was not associated with child FPG, whereas association of GDM with child 2-h glucose was demonstrated in a group of 890 children. The present study also demonstrated no association of GDM with child FPG but did demonstrate that, after adjustment for both maternal and child BMI, GDM was associated with not only child 2-h glucose but also with 30-min and 1-h PG.

We have demonstrated associations of GDM according to IADPSG/WHO criteria with offspring obesity and adiposity in the HAPO FUS cohort (13). However, despite the known impact of childhood obesity on glucose metabolism (25), a singular feature of the current report is that association of GDM with childhood IGT was not attenuated by adjusting for the child's BMI z-score or other measures of adiposity or maternal BMI during pregnancy. Compared with mothers without GDM, mothers with GDM more frequently have a family history of type 2 diabetes and are at higher risk for developing

type 2 diabetes (31; 32). Offspring of mothers with GDM in this study more frequently had a family history of diabetes in first degree relatives; however, the association of maternal GDM with child IGT was independent of the child's family history of diabetes. Together, these data demonstrate that GDM is associated with an independent risk for offspring IGT, suggesting that fetal programming may contribute to the observed associations, although additional factors, e.g., shared environmental factors and shared genetics not captured by family history of diabetes, may also contribute. Importantly, this study also demonstrated that the risk of IGT in offspring of mothers with GDM occurred with lesser degrees of hyperglycemia during pregnancy compared with GDM diagnostic thresholds employed in earlier studies. Consistent with that, exploratory analyses that removed women with Carpenter-Coustan GDM showed that GDM according to IADPSG/WHO criteria was significantly associated with child IGT and other measures of glucose metabolism compared with mothers without GDM.

Previous studies have demonstrated association of maternal diabetes with offspring insulin resistance during childhood (25; 33; 34). In the present study, insulin sensitivity was also lower in offspring of mothers with GDM compared with those without GDM. Adjusting for child BMI or adiposity attenuated the association of GDM with insulin sensitivity, but the association remained significant, suggesting that it was, in part, independent of child BMI and adiposity. Insulin resistance is an early abnormality in children with abnormal glucose metabolism and major driving force behind dysglycemia in adolescents (35). Progression to type 2 diabetes in children occurs, in part, secondary to a rapid decline in beta cell function (36-38). We found that offspring

of mothers with GDM had, on average, a lower insulinogenic index, but the association was borderline significant only after adjusting for both maternal BMI during pregnancy and child's BMI z-score. However, the oral disposition index in offspring of GDM mothers was consistently lower than in offspring of mothers without GDM. This is consistent with a beta cell defect in these children, manifest as limited beta cell compensation for the underlying insulin resistance. Greater insulin resistance together with lower disposition index is seen in individuals who tend to progress to type 2 diabetes (39; 40) and likely contributes to the higher risk for IGT in offspring of GDM mothers.

Of particular note in this study was the positive association of GDM with the child's 30 min, 1-h, and 2-h PG but not FPG. Similarly, GDM was associated with a higher risk of IGT but not IFG-ADA. IFG and IGT are considered to be distinct metabolic conditions with differing pathophysiologies (41; 42). Isolated IFG is thought to reflect high hepatic insulin resistance with relatively normal insulin sensitivity in skeletal muscle, while those with isolated IGT typically exhibit insulin resistance in skeletal muscle (41). Thus, GDM may preferentially impact offspring skeletal muscle as opposed to liver.

Strengths of the study include that HAPO was a blinded observational study in which both caregivers and mothers were unaware of maternal glucose levels; thus, child outcomes were not confounded by treatment of maternal hyperglycemia. Also, HAPO

included participants from multiple races and ethnicities from field centers around the world making the results broadly applicable.

This study had some limitations. First, the proportion of participants who met IADPSG/WHO criteria and participated in the HAPO FUS (weighted estimate 14.9%) is lower than in all eligible participants (16.2%). Second, we were unable to diagnose IGT in all participants due to some missing 2-h PG measurements. Participants with a normal FPG but missing 2-h PG value (n=54) were defined as having normal glucose metabolism; thus, the number of individuals with IGT may have been an underestimate. Third, 1.8% of HAPO participants with OGTT values higher than predefined thresholds were unblinded and excluded from HAPO primary analyses and this study (24). This subgroup would likely have included children at highest risk for IGT. Fourth, the HAPO FUS was not powered to formally examine Tanner stage-specific associations. Fifth, paternal BMI data were not available. Finally, postnatal factors that might influence child glucose outcomes were not available for analyses.

In summary, against a background of limited data and conflicting results, the present large, racially and ethnically diverse study demonstrates that maternal hyperglycemia during pregnancy is associated with a higher risk of IGT in childhood. In addition, this association is evident even when maternal GDM is defined by the less stringent IADPSG/WHO criteria. Importantly, this association persisted after adjustment for maternal BMI and childhood adiposity, which are also associated with GDM in this cohort (13). Given the risk for progression to type 2 diabetes in children with IGT (42),

our findings have important public health implications. A review of trials examining the effect of GDM treatment on child metabolic outcomes reported no difference in offspring of treated vs. non-treated mothers, but the overall strength of evidence was deemed insufficient (43). With the increasing prevalence of GDM and potential transgenerational impact of *in utero* exposure to GDM, future, well-powered interventional trials are needed to address the impact of prevention and treatment of GDM diagnosed using IADPSG/WHO criteria on subsequent childhood glucose outcomes.

Acknowledgments. The HAPO Follow-Up Study investigators are grateful for all mothers and children who participated in HAPO and HAPO Follow-Up Study.

Funding. The HAPO Follow-Up Study is funded by grant 1U01DK094830 from the National Institute of Diabetes, Digestive, and Kidney Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The HAPO Study was funded by from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01-HD-34242 and R01-HD-34243). HAPO Follow-Up Study data were collected and managed using REDCap electronic data capture tools hosted at Northwestern University Feinberg School of Medicine (FSM). REDCap is supported at FSM by the Northwestern University Clinical and Translational Science (NUCATS) Institute. Research reported in this publication was supported, in part, by the National Institutes of Health's National Center for Advancing Translational Sciences, grant UL1TR001422. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author contributions. W.J.B., P.M.C., J.M.L., Y.L., R.C.M., D.M. and W.H.T. acquired data and participated in writing the manuscript. B.E.M., L.P.L., W.L.L. conceived and designed the study, researched the literature, assisted with data collection, interpreted the data, and wrote the manuscript. P.M.C. conceived and designed the study, acquired data, interpreted the data, and wrote the manuscript. J.H. researched the

literature, acquired data, interpreted the data, and wrote the manuscript. B.L. designed the study, interpreted the data, and wrote the manuscript. A.R.D designed the study, acquired data, interpreted the data, and wrote the manuscript. A.K., M.N. and O.T. analyzed the data. D.M.S. researched the literature, designed the study, acquired data, analyzed the data, interpreted the data, and wrote the paper and figures. B.E.M. and D.M.S. are the guarantors of this work and, as such, had full access to all of the data in the study and take responsibility for integrity of the data and the accuracy of the data analysis.

References

1. Viner R, White B, Christie D: Type 2 diabetes in adolescents: a severe phenotype posing major clinical challenges and public health burden. *Lancet* 2017;389:2252-2260
2. Collaboration NCDRF: Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. *Lancet* 2017;
3. Ogden CL, Carroll MD, Lawman HG, Fryar CD, Kruszon-Moran D, Kit BK, Flegal KM: Trends in Obesity Prevalence Among Children and Adolescents in the United States, 1988-1994 Through 2013-2014. *JAMA* 2016;315:2292-2299
4. Imperatore G, Boyle JP, Thompson TJ, Case D, Dabelea D, Hamman RF, Lawrence JM, Liese AD, Liu LL, Mayer-Davis EJ, Rodriguez BL, Standiford D, Group SfDiYS: Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth. *Diabetes Care* 2012;35:2515-2520
5. Metzger BE: Long-term outcomes in mothers diagnosed with gestational diabetes mellitus and their offspring. *Clin Obstet Gynecol* 2007;50:972-979
6. Pettitt DJ, Aleck KA, Baird HR, Carraher MJ, Bennett PH, Knowler WC: Congenital susceptibility to NIDDM. Role of intrauterine environment. *Diabetes* 1988;37:622-628
7. Silverman BL, Metzger BE, Cho NH, Loeb CA: Impaired glucose tolerance in adolescent offspring of diabetic mothers. Relationship to fetal hyperinsulinism. *Diabetes Care* 1995;18:611-617
8. Landon MB, Rice MM, Varner MW, Casey BM, Reddy UM, Wapner RJ, Rouse DJ, Biggio JR, Jr., Thorp JM, Chien EK, Saade G, Peaceman AM, Blackwell SC, VanDorsten JP, Eunice Kennedy Shriver National Institute of Child H, Human Development Maternal-Fetal Medicine Units N: Mild gestational diabetes mellitus and long-term child health. *Diabetes Care* 2015;38:445-452
9. Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA: Hyperglycemia and adverse pregnancy outcomes. *N Engl J Med* 2008;358:1991-2002
10. International association of diabetes and pregnancy groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care* 2010;33:676-682
11. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline. *Diabetes Res Clin Pract* 2014;103:341-363
12. Carpenter MW, Coustan DR: Criteria for screening tests for gestational diabetes. *Am J Obstet Gynecol* 1982;144:768-773
13. Lowe JW, Scholtens DM, Lowe LP, Kuang A, Nodzinski M, Talbot O, Catalano PM, Linder B, Brickman WJ, Clayton PE, Deerochanawong C, Hamilton J, Josefson JL, Lashley M, Lawrence JM, Lebenthal Y, Ma RC, Maresh M, McCance DR, W.H. T, Sacks DA, Dyer AR, Metzger BE: Association of gestational diabetes with subsequent maternal disorders of glucose metabolism and childhood adiposity. *JAMA* 2018; 320(10):1005-1016.
14. Manley SE, Stratton IM, Clark PM, Luzio SD: Comparison of 11 human insulin assays: implications for clinical investigation and research. *Clin Chem* 2007;53:922-932
15. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. *Diabetes Care* 1999;22:1462-1470
16. Phillips DI, Clark PM, Hales CN, Osmond C: Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. *Diabet Med* 1994;11:286-292
17. Weiss R, Cali AM, Dziura J, Burgert TS, Tamborlane WV, Caprio S: Degree of obesity and glucose allostasis are major effectors of glucose tolerance dynamics in obese youth. *Diabetes Care* 2007;30:1845-1850

18. Cheung YB: A modified least-squares regression approach to the estimation of risk difference. *Am J Epidemiol* 2007;166:1337-1344
19. Team RC: *A Language and Environment for Statistical Computing*. Vienna, Austria, R Foundation for Statistical Computing, 2016
20. Cole TJ, Lobstein T: Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. *Pediatric obesity* 2012;7:284-294
21. Hosmer DW, Lemeshow S: *Applied Logistic Regression*. New York, Wiley, 2013
22. Kelly LA, Lane CJ, Weigensberg MJ, Toledo-Corral CM, Goran MI: Pubertal changes of insulin sensitivity, acute insulin response, and beta-cell function in overweight Latino youth. *J Pediatr* 2011;158:442-446
23. Lawrence JM, Contreras R, Chen W, Sacks DA: Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. *Diabetes Care* 2008;31:899-904
24. Sacks DA, Hadden DR, Maresh M, Deerochanawong C, Dyer AR, Metzger BE, Lowe LP, Coustan DR, Hod M, Oats JJ, Persson B, Trimble ER, Group HSCR: Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. *Diabetes Care* 2012;35:526-528
25. Giannini C, Dalla Man C, Groop L, Cobelli C, Zhao H, Shaw MM, Duran E, Pierpont B, Bale AE, Caprio S, Santoro N: Co-occurrence of risk alleles in or near genes modulating insulin secretion predisposes obese youth to prediabetes. *Diabetes Care* 2014;37:475-482
26. Holder T, Giannini C, Santoro N, Pierpont B, Shaw M, Duran E, Caprio S, Weiss R: A low disposition index in adolescent offspring of mothers with gestational diabetes: a risk marker for the development of impaired glucose tolerance in youth. *Diabetologia* 2014;57:2413-2420
27. Plagemann A, Harder T, Kohlhoff R, Rohde W, Dorner G: Glucose tolerance and insulin secretion in children of mothers with pregestational IDDM or gestational diabetes. *Diabetologia* 1997;40:1094-1100
28. Tam WH, Ma RCW, Ozaki R, Li AM, Chan MHM, Yuen LY, Lao TTH, Yang X, Ho CS, Tutino GE, Chan JCN: In Utero Exposure to Maternal Hyperglycemia Increases Childhood Cardiometabolic Risk in Offspring. *Diabetes Care* 2017;40:679-686
29. Donovan LE, Cundy T: Does exposure to hyperglycaemia in utero increase the risk of obesity and diabetes in the offspring? A critical reappraisal. *Diabet Med* 2015;32:295-304
30. Kawasaki M, Arata N, Miyazaki C, Mori R, Kikuchi T, Ogawa Y, Ota E: Obesity and abnormal glucose tolerance in offspring of diabetic mothers: A systematic review and meta-analysis. *PLoS One* 2018;13:e0190676
31. Bellamy L, Casas JP, Hingorani AD, Williams D: Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. *Lancet* 2009;373:1773-1779
32. Zhu Y, Zhang C: Prevalence of Gestational Diabetes and Risk of Progression to Type 2 Diabetes: a Global Perspective. *Curr Diab Rep* 2016;16:7
33. Bush NC, Chandler-Laney PC, Rouse DJ, Granger WM, Oster RA, Gower BA: Higher maternal gestational glucose concentration is associated with lower offspring insulin sensitivity and altered beta-cell function. *J Clin Endocrinol Metab* 2011;96:E803-809
34. Lacroix M, Kina E, Hivert MF: Maternal/fetal determinants of insulin resistance in women during pregnancy and in offspring over life. *Curr Diab Rep* 2013;13:238-244
35. Chen ME, Chandramouli AG, Considine RV, Hannon TS, Mather KJ: Comparison of beta-Cell Function Between Overweight/Obese Adults and Adolescents Across the Spectrum of Glycemia. *Diabetes Care* 2017;
36. Bacha F, Gungor N, Lee S, Arslanian SA: Progressive deterioration of beta-cell function in obese youth with type 2 diabetes. *Pediatr Diabetes* 2013;14:106-111

37. Bacha F, Lee S, Gungor N, Arslanian SA: From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. *Diabetes Care* 2010;33:2225-2231
38. Burns SF, Bacha F, Lee SJ, Tfayli H, Gungor N, Arslanian SA: Declining beta-cell function relative to insulin sensitivity with escalating OGTT 2-h glucose concentrations in the nondiabetic through the diabetic range in overweight youth. *Diabetes Care* 2011;34:2033-2040
39. Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Nissen M, Isomaa B, Forsen B, Homstrom N, Saloranta C, Taskinen MR, Groop L, Tuomi T, Botnia study g: Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. *Diabetes* 2005;54:166-174
40. Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M: What is the best predictor of future type 2 diabetes? *Diabetes Care* 2007;30:1544-1548
41. Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M: Prediabetes: a high-risk state for diabetes development. *Lancet* 2012;379:2279-2290
42. Weiss R, Santoro N, Giannini C, Galderisi A, Umamo GR, Caprio S: Prediabetes in youth - mechanisms and biomarkers. *Lancet Child Adolesc Health* 2017;1:240-248
43. Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L: Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. *Ann Intern Med* 2013;159:123-129

Table 1. Characteristics of Mothers during HAPO Pregnancy OGTT and their Children at Follow-Up According to Mother's GDM Status

Characteristics - Mothers	Overall	GDM*	No GDM
During HAPO Pregnancy	N=4160	N=589	N=3571
	Mean (SD)	Mean (SD)	Mean (SD)
Age at OGTT (yrs)	29.9 (5.7)	31.8 (5.3)	29.6 (5.7)
Gestational Age at OGTT (wks)	27.6 (1.7)	27.9 (1.7)	27.6 (1.7)
Height (cm)	161.7 (6.8)	160.9 (7.0)	161.8 (6.8)
Weight (kg)	71.8 (14.1)	77.2 (15.9)	70.9 (13.6)
Body Mass Index (BMI) (kg/m ²)	27.4 (4.9)	29.7 (5.4)	27.0 (4.7)
Mean Arterial Pressure (mmHg)	80.2 (7.9)	83.3 (7.7)	79.7 (7.8)
Fasting Plasma Glucose (mmol/l)	4.5 (0.4)	4.9 (0.4)	4.4 (0.3)
1-h Plasma Glucose (mmol/l)	7.4 (1.7)	9.6 (1.6)	7.0 (1.4)
2-h Plasma Glucose (mmol/l)	6.1 (1.3)	7.7 (1.5)	5.9 (1.1)
	N (%)	N (%)	N (%)
Race/Ethnicity			
White, Non-Hispanic	1778 (42.7)	215 (36.5)	1563 (43.8)
Hispanic	465 (11.2)	104 (17.7)	361 (10.1)
Black, Non-Hispanic	719 (17.3)	71 (12.1)	648 (18.1)
Asian	1125 (27.0)	184 (31.2)	941 (26.4)
Other	73 (1.8)	15 (2.5)	58 (1.6)
Any Prenatal Smoking	177 (4.3)	33 (5.6)	144 (4.0)
Any Prenatal Alcohol Use	283 (6.8)	39 (6.6)	244 (6.8)
Parity (any prior delivery \geq 20 weeks)	2146 (51.6)	334 (56.7)	1812 (50.7)
Characteristics - Children	Mean (SD)	Mean (SD)	Mean (SD)
At Follow-Up			
Age (yrs)	11.4 (1.2)	11.4 (1.3)	11.3 (1.2)
Height (cm)	148.5 (10.4)	149.4 (9.9)	148.4 (10.4)
Weight (kg)	43.2 (13.6)	45.9 (14.5)	42.7 (13.4)
BMI z-score	0.47 (1.25)	0.73 (1.31)	0.43 (1.24)
Sum of skinfolds (mm)	38.8 (21.3)	43.6 (23.8)	38.1 (20.8)
	N (%)	N (%)	N (%)
Sex – Female	2036 (48.9)	272 (46.2)	1764 (49.4)
Tanner Stage - Girls			
1	340 (19.0)	39 (16.0)	301 (19.5)
2/3	761 (42.6)	108 (44.4)	653 (42.3)
4/5	686 (38.4)	96 (39.5)	590 (38.2)
Tanner Stage - Boys			
1	523 (35.8)	66 (31.4)	457 (36.6)
2/3	673 (46.1)	100 (47.6)	573 (45.9)
4/5	263 (18.0)	44 (21.0)	219 (17.5)
Family History of Diabetes	1899 (45.7)	358 (60.8)	1541 (43.2)
Outcomes - Children	Mean (SD)	Mean (SD)	Mean (SD)

Fasting glucose (mmol/l)	5.0 (0.4)	5.1 (0.4)	5.0 (0.4)
30 min glucose (mmol/l)	7.8 (1.3)	8.2 (1.4)	7.7 (1.3)
1-h glucose (mmol/l)	6.8 (1.7)	7.3 (1.8)	6.8 (1.7)
2-h glucose (mmol/l)	6.0 (1.2)	6.2 (1.2)	5.9 (1.1)
Sum of glucose z-scores	-0.01 (2.8)	0.9 (2.9)	-0.2 (2.8)
Matsuda index	1810.9 (747.3)	1620.0 (681.8)	1838.4 (753.3)
Insulinogenic index	0.82 (0.69)	0.78 (0.64)	0.82 (0.70)
Disposition index	7.02 (0.58)	6.88 (0.59)	7.05 (0.57)
	N (%)	N (%)	N (%)
IFG-ADA	316 (7.6)	54 (9.2)	262 (7.4)
IFG-WHO	23 (0.6)	3 (0.5)	20 (0.6)
IGT	238 (5.8)	61 (10.6)	177 (5.0)
Type 2 diabetes	10 (0.2)	2 (0.3)	8 (0.2)

GDM=gestational diabetes mellitus defined by IADPSG criteria (1 or more glucose values from a 75g

OGTT equals or exceeds FPG 5.1 mmol/l, 1-hr 10.0 mmol/l, 2-hr 8.5 mmol/l)

IFG-ADA=impaired fasting glucose defined by ADA criteria (FPG 5.6-6.9 mmol/l)

IFG-WHO=impaired fasting glucose defined by WHO criteria (FPG 6.1-6.9 mmol/l)

IGT=impaired glucose tolerance (2-h PG 7.8-11.0 mmol/l)

Type 2 diabetes (FPG \geq 7.0 and/or 2-h PG \geq 11.0 mmol/l)

Disposition index is reported on a log scale

Table 2. Association of Maternal GDM Status during Pregnancy with Child Glucose Outcomes

Continuous Child Metabolic Outcomes	Model 1 Beta (95% CI) p-value, R²	Model 2 Beta (95% CI) p-value, R²	Model 3 Beta (95% CI) p-value, R²	Model 4 Beta (95% CI) p-value, R²
Fasting glucose (mmol/l)	0.026 (-0.0056 – 0.056) p=0.11, 0.23	0.024 (-0.0072 – 0.055) p=0.13, 0.23	0.021 (-0.0094 – 0.052) p=0.18, 0.23	0.022 (-0.0083 – 0.053) p=0.16, 0.23
30 min glucose (mmol/l)	0.27 (0.16-0.39) p<0.0001, 0.12	0.28 (0.17-0.40) p<0.0001, 0.12	0.27 (0.15-0.38) p<0.0001, 0.12	0.28 (0.16-0.40) p<0.0001, 0.12
1-h glucose (mmol/l)	0.34 (0.19-0.49) p<0.0001, 0.071	0.35 (0.20-0.50) p<0.0001, 0.072	0.33 (0.18-0.48) p<0.0001, 0.072	0.35 (0.20-0.50) p<0.0001, 0.072
2-h glucose (mmol/l)	0.20 (0.10-0.30) p<0.0001, 0.079	0.20 (0.10-0.30) p<0.0001, 0.079	0.18 (0.08-0.28) p=0.0004, 0.095	0.20 (0.10-0.30) p=0.0001, 0.096
Sum of glucose z-scores	0.65 (0.41-0.88) p<0.0001, 0.17	0.66 (0.42-0.90) p<0.0001, 0.17	0.61 (0.37-0.84) p<0.0001, 0.17	0.65 (0.41-0.88) p<0.0001, 0.17
Matsuda index	-114.5 (-174.5- -54.5) p=0.0002, 0.22	-91.6 (-151.6- -31.6) p=0.0031, 0.23	-70.9 (-124.4- -17.5) p=0.010, 0.38	-76.3 (-130.3- -22.4) p=0.0063, 0.38
Insulinogenic index	-0.034 (-0.10-0.029) p=0.28, 0.052	-0.053 (-0.12-0.010) p=0.10, 0.058	-0.052 (-0.11-0.010) p=0.10, 0.080	-0.060 (-0.120-0.0030) p=0.061, 0.081
Disposition index	-0.12 (-0.17- -0.06) p<0.0001, 0.071	-0.12 (-0.18- -0.065) p<0.0001, 0.071	-0.11 (-0.17- -0.057) p<0.0001, 0.073	-0.12 (-0.17- -0.064) p<0.0001, 0.074

*GDM=gestational diabetes mellitus defined by IADPSG criteria (1 or more glucose values from a 75g OGTT equals or exceeds FPG 5.1 mmol/l, 1-h 10.0 mmol/l, 2-h 8.5 mmol/l)

Model 1: Adjusted for field center + child age, sex, pubertal status (Tanner stage 1, 2/3, 4/5, sex x Tanner stage interaction) + maternal variables at pregnancy OGTT (age, height, mean arterial pressure, parity (0, 1+), smoking (yes/no), drinking (yes/no), gestational age), child's family history of diabetes in first degree relatives. Model 2: Model 1 + maternal BMI at pregnancy OGTT. Model 3: Model 1 + child's BMI z-score. Model 4: Model 1 + maternal BMI at pregnancy OGTT + child's BMI z-score.

Table 3. Association of Maternal GDM Status during Pregnancy with Dichotomous Child Metabolic Outcomes

Dichotomous Child Glucose Outcome	Model 1		Model 2		Model 3		Model 4	
	OR (95% CI) p-value C-statistic	Risk Difference (95% CI) p-value	OR (95% CI) p-value C-statistic	Risk Difference (95% CI) p-value	OR (95% CI) p-value C-statistic	Risk Difference (95% CI) p-value	OR (95% CI) p-value C-statistic	Risk Difference (95% CI) p-value
IFG-ADA	1.11 (0.79-1.54) p=0.55 C=0.78	0.0066 (-0.018-0.031) p=0.60	1.11 (0.79-1.54) p=0.58 C=.78	0.0063 (-0.019-0.031) p=0.62	1.09 (0.78-1.52) p=0.62 C=.78	0.005 (-0.019-0.031) p=0.54	1.09 (0.78-1.52) p=0.61 C=.78	0.005 (-0.019-0.031) p=0.64
IGT	1.91 (1.38-2.64) p<0.0001 C=0.70	0.046 (0.020-0.071) p=0.0004	1.96 (1.41-2.72) p<0.0001 C=0.70	0.047 (0.022-0.073) p=0.0003	1.87 (1.35-2.59) p=0.0001 C=0.71	0.044 (0.019-0.070) p=0.0007	1.96 (1.41-2.73) p<0.0001 C=0.71	0.047 (0.021-0.072) p=0.0004

GDM=gestational diabetes mellitus defined by IADPSG criteria (1 or more glucose values from a 75g OGTT equals or exceeds FPG 5.1 mmol/l, 1-h 10.0 mmol/l, 2-h 8.5 mmol/l)

IFG-ADA=impaired fasting glucose defined by ADA criteria (FPG 5.6-6.9 mmol/l)

IGT=impaired glucose tolerance (2-h PG 7.8-11.0 mmol/l)

Model 1: Adjusted for field center + child age, sex, pubertal status (Tanner stage 1, 2/3, 4/5, sex x Tanner stage interaction) + maternal variables at pregnancy OGTT (age, height, mean arterial pressure, parity (0, 1+), smoking (yes/no), drinking (yes/no), gestational age), child's family history of diabetes in first degree relatives. Model 2: Model 1 + maternal BMI at pregnancy OGTT. Model 3: Model 1 + child's BMI z-score. Model 4: Model 1 + maternal BMI at pregnancy OGTT + child's BMI z-score.

Figure Legends

Figure 1. ORs (95% CIs), p-values and C-statistics from logistic regression analyses and Risk Differences (95% CIs) and p-values for the association of maternal GDM during pregnancy with outcomes in HAPO FUS children: A-B) IGT; C-D) IFG-ADA. Results are presented for each outcome for Model 1 (purple), Model 2 (blue), Model 3 (green) and Model 4 (orange) covariates.

Table S1. Characteristics of HAPO FUS Participants and Non-Participants

HAPO Maternal Characteristics	Participants N=4832	Non-Participants N=10980	Participants N=4832	Non-Participants N=10980
	Unweighted Summaries		Weighted Summaries*	
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
Age at OGTT(yrs)	29.9 (5.7)	29.1 (5.7)	30.0 (5.1)	29.1 (5.3)
Body Mass Index (BMI)	27.5 (4.9)	27.5 (5.1)	27.5 (4.6)	27.5 (4.7)
Height (cm)	161.8 (6.8)	160.7 (7.3)	161.1 (6.2)	160.9 (6.3)
Fasting Plasma Glucose (mmol/l)	4.5 (0.4)	4.5 (0.4)	4.5 (0.4)	4.5 (0.4)
1-hr Plasma Glucose (mmol/l)	7.4 (1.7)	7.5 (1.7)	7.5 (1.7)	7.5 (1.7)
2-hr Plasma Glucose (mmol/l)	6.1 (1.3)	6.2 (1.3)	6.2 (1.3)	6.2 (1.3)
	N (%)	N (%)	(%)	(%)
GDM	683 (14.1)	1879 (17.1)	(14.9)	(16.9)
Race/Ethnicity				
White, non-Hispanic	2287 (47.3)	4705 (42.9)	(44.5)	(44.1)
Hispanic	507 (10.5)	1047 (9.5)	(10.3)	(9.6)
Black, non-Hispanic	775 (16.0)	1551 (14.1)	(14.8)	(14.6)
Asian	1176 (24.3)	3424 (31.2)	(28.5)	(29.3)
Other	87 (1.8)	253 (2.3)	(1.8)	(2.3)

* Weighted summaries are weighted means and standard deviations or weighted percentages based on field-center-specific summary statistics with weights proportional to the total eligible population at the field center.

**GDM=gestational diabetes mellitus defined by IADPSG criteria (1 or more glucose values from a 75g OGTT equals or exceeds FPG 5.1 mmol/l, 1-hr 10.0 mmol/l, 2-hr 8.5 mmol/l)

Table S2. Association of Maternal GDM Status during Pregnancy with Continuous Child Metabolic Outcomes

Continuous Child Glucose Outcome	Model 5 Beta (95% CI) p-value, R²	Model 6 Beta (95% CI) p-value, R²	Model 7 Beta (95% CI) p-value, R²	Model 8 Beta (95% CI) p-value, R²
Fasting glucose (mmol/l)	0.021 (-0.0096-0.052) p=0.18, 0.23	0.021 (-0.0095-0.053) p=0.17, 0.23	0.021 (-0.0096-0.052) p=0.18, 0.23	0.021 (-0.0096-0.052) p=0.18, 0.23
30 min glucose (mmol/l)	0.26 (0.15-0.38) p<0.0001, 0.12	0.28 (0.17-0.40) p<0.0001, 0.12	0.27 (0.15-0.38) p<0.0001, 0.12	0.28 (0.17-0.40) p<0.0001, 0.12
1-h glucose (mmol/l)	0.31 (0.16-0.46) p<0.0001, 0.079	0.33 (0.18-0.48) p<0.0001, 0.081	0.31 (0.16-0.45) p<0.0001, 0.079	0.33 (0.18-0.48) p<0.0001, 0.081
2-h glucose (mmol/l)	0.17 (0.067-0.26) p=0.0010, 0.11	0.18 (0.083-0.28) p=0.0003, 0.11	0.16 (0.064-0.26) p=0.0012, 0.11	0.18 (0.080-0.28) p=0.0004, 0.11
Sum of glucose z-scores	0.58 (0.35-0.82) p<0.001, 0.18	0.62 (0.39-0.86) p<0.001, 0.18	0.58 (0.35-0.82) p<0.001, 0.18	0.62 (0.39-0.86) p<0.001, 0.18
Matsuda index	-59.8 (-113.0- -6.6) p=0.028, 0.40	-60.9 (-114.5- -7.4) p=0.026, 0.40	-58.5 (-112.6- -4.4) p=0.034, 0.38	-58.4 (-112.8- -4.0) p=0.035, 0.38
Insulinogenic index	-0.055 (-0.12-0.0083) p=0.091, 0.076	-0.064 (-0.13- -0.0012) p=0.046, 0.078	-0.055 (-0.12-0.0077) p=0.087, 0.074	-0.065 (-0.13-0.0018) p=0.043, 0.077
Disposition index	-0.11 (-0.16- -0.05) p=0.0001, 0.78	-0.11 (-0.17- -0.06) p<0.0001, 0.79	-0.11 (-0.16- -0.05) p=0.0001, 0.77	-0.11 (-0.17- -0.06) p<0.0001, 0.78

*GDM=gestational diabetes mellitus defined by IADPSG criteria (1 or more glucose values from a 75g OGTT equals or exceeds FPG 5.1 mmol/l, 1-hr 10.0 mmol/l, 2-hr 8.5 mmol/l). Disposition index was log transformed for analysis.

Model 1: Adjusted for field center + child age, sex, pubertal status (Tanner stage 1, 2/3, 4/5, sex x Tanner stage interaction) + maternal variables at pregnancy OGTT (age, height, mean arterial pressure, parity (0, 1+), smoking (yes/no), drinking (yes/no), gestational age), child's family history of diabetes in first degree relatives. Model 5: Model 1 + child's percent body fat. Model 6: Model 1 + maternal BMI at pregnancy OGTT + child's percent body fat. Model 7: Model 1 + child's sum of skinfolds. Model 8: Model 1 + maternal BMI at pregnancy OGTT + child's sum of skinfolds.

Table S3. Association of Maternal GDM Status during Pregnancy with Dichotomous Child Metabolic Outcomes

Dichotomous Child Glucose Outcome	Model 5		Model 6		Model 7		Model 8	
	OR (95% CI) p-value, C-statistic	Risk Difference (95% CI) p-value	OR (95% CI) p-value, C-statistic	Risk Difference (95% CI) p-value	OR (95% CI) p-value, C-statistic	Risk Difference (95% CI) p-value	OR (95% CI) p-value, C-statistic	Risk Difference (95% CI) p-value
IFG-ADA	1.09 (0.78-1.52) p=0.60 C=0.78	0.0057 (-0.019-0.031) p=0.66	1.09 (0.78-1.53) p=0.61 C=.78	0.0057 (-0.019-0.031) p=0.65	1.09 (0.78-1.52) p=0.60 C=.78	0.0057 (-0.019-0.031) p=0.65	1.09 (0.78-1.53) p=0.61 C=.78	0.0057 (-0.019-0.031) p=0.65
IGT	1.82 (1.31-2.52) p=0.0003 C=0.72	0.043 (0.017-0.068) p=0.0010	1.92 (1.38-2.67) p=0.0001 C=0.72	0.045 (0.020-0.071) p=0.0005	1.82 (1.31-2.52) p=0.0003 C=0.72	0.042 (0.017-0.067) p=0.0012	1.92 (1.38-2.68) p=0.0001 C=0.72	0.045 (0.019-0.070) p=0.0006

GDM=gestational diabetes mellitus defined by IADPSG criteria (1 or more glucose values from a 75g OGTT equals or exceeds FPG 5.1 mmol/l, 1-hr 10.0 mmol/l, 2-hr 8.5 mmol/l)

IFG-ADA=impaired fasting glucose defined by ADA criteria (FPG 5.6-6.9 mmol/l)

IGT=impaired glucose tolerance (2-h PG 7.8-11.0 mmol/l)

Model 1: Adjusted for field center + child age, sex, pubertal status (Tanner stage 1, 2/3, 4/5, sex x Tanner stage interaction) + maternal variables at pregnancy OGTT (age, height, mean arterial pressure, parity (0, 1+), smoking (yes/no), drinking (yes/no), gestational age), child's family history of diabetes in first degree relatives. Model 5: Model 1 + child's percent body fat. Model 6: Model 1 + maternal BMI at pregnancy OGTT + child's percent body fat. Model 7: Model 1 + child's sum of skinfolds. Model 8: Model 1 + maternal BMI at pregnancy OGTT + child's sum of skinfolds.

Table S4. Tanner Stage Specific Associations between Maternal GDM during pregnancy and Child Metabolic Outcomes

	Tanner Stage 1	Tanner Stage 2/3	Tanner Stage 4/5
Child Dichotomous Outcomes	OR* (95% CI), p		
IFG-ADA	1.22 (0.57-2.62), p=0.61	1.54 (0.90-2.62), p=0.11	0.41 (0.16-1.02), p=0.06
IGT	2.17 (0.85-5.58), p=0.11	1.60 (0.93-2.77), p=0.09	3.02 (1.45-6.31), p=0.003
Child Continuous Outcomes	Adjusted Mean Difference* (95% CI), p		
Fasting glucose (mmol/l)	0.015 (-0.061-0.091), p=0.70	0.020 (-0.031-0.072), p=0.44	-0.0080 (-0.073-0.057), p=0.81
30 min glucose (mmol/l)	0.11 (-0.17-0.39), p=0.44	0.34 (0.15-0.52), p=0.0005	0.41 (0.18-0.63), p=0.0005
1-h glucose (mmol/l)	0.16 (-0.20-0.53), p=0.37	0.46 (0.21-0.72), p=0.0004	0.49 (0.19-0.78), p=0.0013
2-h glucose (mmol/l)	0.10 (-0.12-0.33), p=.38	0.13 (-0.032-0.30), p=0.12	0.28 (0.081-0.49), p=0.0062
Sum of glucose z-scores	0.16 (-0.42-0.74), p=0.59	0.75 (0.35-1.15), p=0.0002	0.89 (0.38-1.39), p=0.0006
Matsuda index	-67.3 (-204.1-69.5), p=0.34	-102.0 (-196.3- -7.7), p=0.034	-50.4 (-145.7-45.0), p=0.30
Insulinogenic index	-0.04 (-0.18-0.10), p=0.60	-0.03 (-0.12-0.06), p=0.47	-0.23 (-0.40- -0.06), p=0.010
Disposition index	-0.07 (-.19-0.05), p=0.28	-0.13 (-0.23- -0.05), p=0.003	-0.20 (-0.31- -0.09), p=0.0005

GDM=gestational diabetes mellitus defined by IADPSG criteria (1 or more glucose values from a 75g OGTT equals or exceeds FPG 5.1 mmol/l, 1-hr 10.0 mmol/l, 2-hr 8.5 mmol/l)

*Association results use fully adjusted Model 4: Adjusted for field center + child age, sex, pubertal status (Tanner stage 1, 2/3, 4/5, sex x Tanner stage interaction) + maternal variables at pregnancy OGTT (age, height, mean arterial pressure, parity (0, 1+), smoking (yes/no), drinking (yes/no), gestational age), child's family history of diabetes in first degree relatives + maternal BMI at pregnancy OGTT + child's BMI z-score.

Table S5. Child Metabolic Outcomes for Maternal GDM during Pregnancy by Carpenter-Coustan Criteria, GDM by IADPSG/WHO Criteria only, and No GDM


	Carpenter-Coustan GDM	IADPSG/WHO Only GDM	No GDM	IADPSG/WHO Only GDM v. No GDM*	
Child Dichotomous Outcomes	N/N Total (%)			OR (95% CI)	p-value
IFG-ADA	15/143 (10.5)	39/444 (8.8)	262/3563 (7.4)	0.99 (0.65-1.52)	0.97
IGT	25/140 (17.9)	36/436 (8.3)	177/3518 (5.0)	1.64 (1.04-2.58)	0.033
Child Continuous Outcomes	Mean (SD)			Adjusted Mean Difference (95% CI)	p-value
Fasting glucose (mmol/l)	5.1 (0.4)	5.0 (0.4)	5.0 (0.4)	-0.0028 (-0.042-0.036)	0.89
30 min glucose (mmol/l)	8.3 (1.5)	8.1 (1.3)	7.7 (1.3)	0.28 (0.14-0.43)	0.0001
1-h glucose (mmol/l)	7.5 (2.0)	7.2 (1.7)	6.8 (1.7)	0.34 (0.15-0.53)	0.0004
2-h glucose (mmol/l)	6.4 (1.3)	6.2 (1.2)	5.9 (1.1)	0.13 (0.0068-0.25)	0.039
Sum of glucose z-scores	1.3 (3.3)	0.7 (2.8)	-0.2 (2.8)	0.54 (0.23-0.84)	0.0005
Matsuda index	1542.3 (703.7)	1645.8 (673.3)	1838.4 (753.3)	-52.3 (-121.3-16.7)	0.14
Insulinogenic index	0.81 (0.57)	0.78 (0.66)	0.82 (0.70)	-0.10 (-0.18- -0.020)	0.015
Disposition index	6.85 (0.62)	6.89 (0.58)	7.05 (0.57)	-0.13 (-0.20- -0.063)	0.0002

Carpenter-Coustan GDM=gestational diabetes mellitus defined by Carpenter-Coustan criteria (2 or more glucose values from a 75g OGTT equals or exceeds FPG 5.3 mmol/l, 1-hr 10.0 mmol/l, 2-hr 8.6 mmol/l)

IADPSG/WHO Only GDM=gestational diabetes mellitus defined by IADPSG/WHO criteria (1 or more glucose values from a 75g OGTT equals or exceeds FPG 5.1 mmol/l, 1-hr 10.0 mmol/l, 2-hr 8.5 mmol/l) but not meeting Carpenter-Coustan Criteria

*Association results remove Carpenter-Coustan GDM mothers from analysis and use fully adjusted Model 4: Adjusted for field center + child age, sex, pubertal status (Tanner stage 1, 2/3, 4/5, sex x Tanner stage interaction) + maternal variables at pregnancy OGTT (age, height, mean arterial pressure, parity (0, 1+), smoking (yes/no), drinking (yes/no), gestational age), child's family history of diabetes in first degree relatives + maternal BMI at pregnancy OGTT + child's BMI z-score.

Supplementary Fig. 1 Flow chart describing enrollment for HAPO FUS.



Odds Ratio (95% CI) p-value, C-statistic


A) IGT

1.91 (1.38-2.64)
p<0.001, C=0.70

1.96 (1.41-2.72)
p<0.001, C=0.70

1.87 (1.35-2.59)
p<0.001, C=0.71

1.96 (1.41-2.73)
p<0.001, C=0.71




B) IGT

0.046 (0.020-0.071)
p<0.001

0.047 (0.022-0.073)
p<0.001

0.044 (0.019-0.070)
p<0.001

0.047 (0.021-0.072)
p<0.001




C) IFG-ADA

1.11 (0.79-1.54)
p=0.55, C=0.78

1.11 (0.79-1.54)
p=0.58, C=0.78

1.09 (0.78-1.52)
p=0.62, C=0.78

1.09 (0.78-1.52)
p=0.61, C=0.78



D) IFG-ADA

0.0066 (-0.018-0.031)
p=0.60

0.0063 (-0.019-0.031)
p=0.62

0.0057 (-0.019-0.031)
p=0.54

0.0059 (-0.019-0.031)
p=0.64

